Clinical Trial Update: Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of zanubrutinib and tafasitamab for Mantle Cell Lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Monjuvi (tafasitamab)

Snippet

Sponsor: Alvaro Alencar, MD | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING